This site is intended for healthcare professionals

Health Canada approves Nypozi biosimilar to Neupogen to treat neutropenia.-Tanvex BioPharma, Inc.

Read time: 1 mins
Published:14th Nov 2021

Nypozi (TX01), a proposed biosimilar to the reference product – Amgen’s Neupogen -- is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever. According to data from IQVIA, filgrastim product sales were close to $100 million (CAD) in the Canada for the 12 months ended June, 2021.

Condition: Neutropenia
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.